Application of levistilide A in preparation of medicine for preventing and / or treating metabolic dysfunction related steatohepatitis
By using oleangi lactone A to solve the treatment difficulties of metabolic dysfunction-related steatohepatitis, oleangi lactone A significantly improves pathological indicators in the mouse and cell models of MASH, with broad market prospects.
Patent Information
- Application Number
- CN202411213142.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-12
AI Technical Summary
There is a lack of effective drug treatment options to deal with the rising incidence of metabolic dysfunction-associated steatohepatitis (MASH).
Orangel lactone A is used as a drug to improve weight changes caused by metabolic dysfunction-related steatohepatitis, reduce serum ALT and AST levels, reduce the number of lipid droplet vacuoles and balloon-like changes, and improve liver steatosis and inflammation. Various dosage forms are used for oral or non-oral administration.
Orangelactone A significantly reduces the number of lipid droplet vacuoles and balloonoid degeneration, improves hepatic steatosis and inflammation, and reduces the ALT, AST, TC and TG content in the serum, and has potential prospects for novel anti-MASH therapeutic drugs.
Smart Images

Figure CN118924738A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of angelica lactone A in the preparation of a drug for preventing and / or treating fatty hepatitis associated with metabolic dysfunction. Background Art
[0002] Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) is a complex liver disease characterized by abnormal accumulation of fat in the liver, accompanied by inflammation, hepatocellular damage, and liver fibrosis. MASH is a more severe form of metabolic dysfunction-associated fatty liver disease (MASLD) and is closely associated with metabolic syndrome, which includes conditions such as obesity, hypertension, diabetes, and dyslipidemia. Efforts to treat MASH have faced many challenges over the past few decades. Despite the increasing incidence of the disease, the lack of effective drug treatment options has been a major problem in the medical community.
[0003] Natural small molecule drugs derived from traditional Chinese medicine have always been an important source for the discovery of new drug lead compounds due to their rich chemical structures and diverse pharmacological activities. Discovering new anti-MASH lead compounds from traditional Chinese medicine is currently a research hotspot.
[0004] Levistilide A (LA) is a relatively new active compound extracted from the medicinal plant Angelica sinensis. Existing studies have shown that Levistilide A can reduce blood lipids and blood sugar, regulate the endocrine and immune systems, and has a significant effect in preventing cardiovascular diseases and fighting cancer. The CAS number of Levistilide A is 88182-33-6, the molecular weight is 380.48, and the structural formula is:
[0005]
[0006] So far, there has been no report on the use of angelica lactone A in the treatment of MASH. Summary of the invention
[0007] In order to overcome the above-mentioned shortcomings of the prior art, the object of the present invention is to provide the use of angelica lactone A in the preparation of a drug for preventing and / or treating fatty hepatitis associated with metabolic dysfunction.
[0008] In order to achieve the above object, the present invention adopts the following technical solutions:
[0009] The first aspect of the present invention discloses the use of angelica lactone A in the preparation of a medicament for preventing and / or treating metabolic dysfunction-related fatty hepatitis.
[0010] Preferably, the drug is a drug that can improve weight gain or weight loss caused by metabolic dysfunction-related fatty hepatitis.
[0011] Preferably, the drug is a drug capable of reducing the ALT level and / or AST level in serum.
[0012] Preferably, the drug is a drug that can reduce the TC content and / or TG content in serum.
[0013] Preferably, the drug is a drug that can reduce the number of lipid droplet vacuoles and ballooning.
[0014] Preferably, the drug is a drug that can improve liver steatosis, lipid accumulation, inflammation in liver lobule or liver fibrosis.
[0015] Preferably, the drug is a drug capable of improving lipid deposition in normal human liver cells or lipid deposition in human liver cancer cells.
[0016] Preferably, the dosage of angelica lactone A is 10 to 20 mg / kg.
[0017] Preferably, the drug is in the form of tablets, capsules, granules, oral liquids, premixes, pills or sustained-release preparations for oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents, or in the form of ointments or injections for non-oral administration.
[0018] The second aspect of the present invention discloses a drug for preventing and / or treating metabolic dysfunction-related fatty liver disease, comprising angelica lactone A and one or more pharmaceutically acceptable carriers and / or excipients, or comprising angelica lactone A and other drugs for treating metabolic dysfunction-related fatty liver disease.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The application of angelica lactone A provided by the present invention in the preparation of a drug for preventing and / or treating metabolic dysfunction-related fatty hepatitis is to simulate the different clinical pathogenesis of MASH by constructing two animal models of MASH in vivo (methionine choline deficiency (MCD) model and high fat and high cholesterol (HFHC) model) to evaluate the beneficial effects of angelica lactone A in treating MASH. The results of liver tissue pathology showed that compared with the model group, angelica lactone A could significantly reduce the number of lipid droplet vacuoles and ballooning, improve hepatic fatty degeneration, inflammation and fibrosis in the liver lobules; reduce the levels of ALT and AST and the contents of TC and TG in serum. In vitro, OA+PA was used to induce L02 and HepG2 to evaluate the efficacy of angelica lactone A, and the results showed that angelica lactone A could significantly reduce the lipid deposition and inflammatory response induced by OA+PA. Therefore, angelica lactone A is expected to be developed as a new anti-MASH therapeutic drug with broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The results of the improvement of the angelica lactone A of the present invention on MASH mice induced by MCD diet; wherein, A: experimental flow chart; B: final body weight; C: liver weight; D: serum ALT level; E: serum AST level; F: serum TC level; G: serum TG content; H: liver photos, liver ultrasound results, H&E staining, Oil Red O staining; I: liver-kidney ratio; J: Oil Red O staining result statistics; n=6, ## P<0.01vs.MCS. ** P<0.01vs.MCD.Scale bar:20μm;
[0022] Figure 2 The figure shows the partial staining results of the improvement effect of angelica lactone A of the present invention on MASH mice induced by MCD diet; wherein, A: Masson staining; B: Masson staining result statistics; C: Sirius red (PSR) staining; D: PSR staining result statistics; n=6, ## P<0.01vs.MCS. ** P<0.01vs.MCD.Scale bar:20μm;
[0023] Figure 3 The results of the improvement of angelica lactone A of the present invention on HFHC diet-induced MASH mice; wherein, A: experimental flow chart; B: final body weight; C: liver weight; D: serum ALT level; E: serum AST level; F: serum TC level; G: serum TG content; H: liver photos, liver ultrasound results, H&E staining, Oil Red O staining; I: liver-kidney ratio; J: Oil Red O staining result statistics; n=6, ## P<0.01vs.Control. ** P<0.01vs.HFHC.Scale bar:20μm;
[0024] Figure 4 This is a partial staining result diagram of the improvement effect of Angelica lactone A of the present invention on HFHC diet-induced MASH mice; wherein, A: Masson staining; B: Masson staining result statistics; C: PSR staining; D: PSR staining result statistics; n=6, ## P<0.01vs.MCS. ** P<0.01vs.MCD.Scale bar:20μm;
[0025] Figure 5The results of the improvement of angelica lactone A of the present invention on OA+PA-induced L02 and HepG2 are shown in the figure; wherein, A: Oil Red O staining and Bodipy fluorescence staining of L02; B: Oil Red O staining statistics of L02; C: Bodipy fluorescence staining statistics of L02; D: Oil Red O staining and Bodipy fluorescence staining of HepG2; E: Oil Red O staining statistics of HepG2; F: Bodipy fluorescence staining statistics of HepG2; ## P<0.01vs.Control. ** P<0.01 vs.FFA.Scale bar:20μm. DETAILED DESCRIPTION
[0026] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.
[0027] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.
[0028] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values within the range (including integers and fractions).
[0029] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”
[0030] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.
[0031] Herein, angelica lactone A can be in any pharmaceutically acceptable form and prepared into any conventional dosage form such as tablets, granules, capsules, dripping pills, premixes, pills, sustained-release preparations, oral solutions, ointments or injections.
[0032] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0033] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The LA used in the following examples was purchased from Baoji Chenguang Biotechnology Co., Ltd., with the item number HR1502W9; the positive drug (Resmetirom, Res) was purchased from TargetMol Chemicals Inc., with the item number 158082. All other raw materials used conventional commercial products, and their specifications are conventional specifications in the art.
[0034] 1. Establishment of animal model (in vivo) and efficacy evaluation
[0035] One hundred SPF C57BL / 6 male mice, 8-9 weeks old, weighing 22-25 g, were housed in the animal room of the Pharmacy Department of the First Affiliated Hospital of Air Force Medical University, with a barrier environment at room temperature of (22±1)°C, relative humidity of 30%-60%, 12 h light / 12 h dark, and free access to food and water.
[0036] Example 1: Evaluation of the efficacy of angelica lactone A using the MASH model induced by MCD diet
[0037] Model building: Figure 1As shown in A, mice were fed with MCD diet for 4 weeks to induce MASH. After the model was successfully established, the modeled mice were randomly divided into a model group (MCD, free drinking water), a low-dose group of angelica lactone A (LA, gavage, 10 mg / kg / day), a high-dose group of angelica lactone A (LA, gavage, 20 mg / kg / day) and a positive drug group (Res, gavage, 15 mg / kg / day), and mice without modeling were used as a control group (MCS, free drinking water). Among them, the mice in the MCS group and the MCD group had free drinking water for 4 weeks, and the mice in each drug group were gavaged with the above drugs for 4 weeks. At the end of the experiment, the mice were fasted for 1 day, blood was collected from the orbital venous plexus, and the serum was separated (3500rpm, 20min, 4℃) and stored in a -80℃ refrigerator. Then, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG) and cholesterol (TC) in the serum of the mice were determined according to the instructions of the kit. The mice were anesthetized and killed, and the livers were quickly removed and cleaned with saline to remove residual blood. The right lobe of the liver was fixed in 4% paraformaldehyde solution and embedded in OTC for liver tissue pathology detection (H&E staining, Oil Red O staining, Masson staining, and Sirius Red (PSR) staining). The remaining liver tissue was placed in a cryovial and quickly frozen with liquid nitrogen and stored in a -80°C refrigerator for later use.
[0038] Efficacy evaluation: (1) Important test indicators: body weight, liver weight; (2) Biochemical indicators: ALT, AST, TG and TC content; (3) Liver pathology: H&E staining, Oil Red O staining, NASH score (hepatic steatosis, intralobular inflammation, hepatocyte ballooning, comprehensive score); (4) Inflammation and fibrosis detection: Masson staining, PSR staining.
[0039] Table 1 Comparison of the liver tissue scores of angelica lactone A in MASH-induced mice with MCD diet (n=6, )
[0040]
[0041] ## P<0.01vs.MCS.*P<0.05,**P<0.01vs.MCD.
[0042] Test results: Figure 1 , Figure 2 As shown in Table 1, Figure 1 and Figure 2 It can be seen that compared with the model group, Angelica lactone A can significantly balance the body weight of mice induced by MCD diet ( Figure 1 B) and liver weight ( Figure 1 C); reduce serum ALT and AST levels ( Figure 1D and E), reduce serum TC and TG levels ( Figure 1 F and G), significantly improved hepatic steatosis, lipid accumulation, intralobular inflammation and liver fibrosis ( Figure 1 Medium H~O, Figure 2 As shown in Table 1, angelica lactone A can improve MASH in mice induced by MCD diet.
[0043] Example 2: Evaluation of the efficacy of angelica lactone A in the MASH model induced by HFHC diet
[0044] Model building: Figure 3 As shown in A, mice were fed HFHC diet for 8 weeks to induce MASH. After the model was successfully established, the modeled mice were randomly divided into a model group (HFHC, free drinking water), a low-dose group of angelica lactone A (LA, gavage, 10 mg / kg / day), a high-dose group of angelica lactone A (LA, gavage, 20 mg / kg / day) and a positive drug group (Res, gavage, 15 mg / kg / day), and mice without modeling were used as a control group (Control, free drinking water). Among them, the mice in the Control group and the HFHC group had free drinking water for 8 weeks, and the mice in each drug group were gavaged with the above drugs for 8 weeks. At the end of the experiment, the mice were fasted for 1 day, but not water, and blood was collected from the orbital venous plexus. The serum was separated (3500rpm, 20min, 4℃) and stored in a -80℃ refrigerator. The mice were anesthetized and killed, and the livers were quickly removed and cleaned with saline to remove residual blood. The right lobe of the liver of all mice was fixed in 4% paraformaldehyde solution and embedded in OTC for liver tissue pathology detection. The remaining liver tissue was placed in a cryovial and quickly frozen with liquid nitrogen and stored in a -80°C refrigerator for later use.
[0045] Efficacy evaluation: (1) Important test indicators: body weight, liver weight; (2) Biochemical indicators: ALT, AST, TG and TC content; (3) Liver pathology: H&E staining, Oil Red O staining, NASH score (hepatic steatosis, intralobular inflammation, hepatocyte ballooning, comprehensive score); (4) Inflammation and fibrosis detection: Masson staining, PSR staining.
[0046] Test results: Figure 3 and Figure 4 As shown in Figure 2, compared with the model group, angelica lactone A could reduce the body weight of mice induced by HFHC diet ( Figure 3 B) and liver weight ( Figure 3 C); reduce serum ALT and AST levels ( Figure 3 D and E), reduce serum TC and TG levels ( Figure 3 F and G), significantly improved hepatic steatosis, lipid accumulation, intralobular inflammation and fibrosis ( Figure 3 Medium H~O, Figure 4 (A-D) Angelica lactone A can improve MASH in mice induced by HFHC diet.
[0047] 2. Establishment of cell model (in vitro) and efficacy evaluation
[0048] Example 3: Sodium oleate (OA) + sodium palmitate (PA) induced hepatic steatosis model in normal human liver cells (L02) and human hepatoma cells (HepG2) to evaluate the efficacy of angelica lactone A
[0049] Model establishment: L02 and HepG2 were cultured in DMEM medium containing 10% fetal bovine serum and 1% double antibody (penicillin-streptomycin mixture) at 37°C and 5% CO 2 When the cell confluence was about 95%, 2×10 5 cell / mL were plated in 6-well plates and randomly divided into 5 groups: blank control group, model group, model + low-dose and high-dose groups of angelica lactone A, and model + positive drug group. After the cells adhered to the wall, the blank control group was given normal culture medium containing DMSO, the model group was given a culture medium mixture containing DMSO and 500μMOA+250μM PA, the model + low-dose and high-dose groups of angelica lactone A were given a culture medium mixture of 10μM and 20μM angelica lactone A and OA+PA, and the model + positive drug group was given a culture medium mixture of Resmetirom 10μM and OA+PA. After mixing, the cells continued to be cultured for 24h.
[0050] Evaluation of therapeutic efficacy: (1) Oil Red O staining. The specific steps are as follows: discard the cell culture medium, wash twice with PBS, add Oil Red O fixative for 20 minutes, remove the fixative and wash twice with distilled water, rinse with 60% isopropanol for 20 seconds and dry, add the newly prepared Oil Red O staining solution, and the staining solution needs to be filtered with a 0.45μm filter membrane before use. Add 500μL of Oil Red O staining solution to each well, soak for 10 minutes, remove the staining solution and wash with PBS for 3 to 5 times until there is no excess staining solution. Soak the stained cells in PBS and observe and take pictures under a microscope. (2) Bodipy fluorescence staining. The specific steps are as follows: discard the cell culture medium, wash twice with PBS, add 4% paraformaldehyde to fix at room temperature for 15 minutes, remove the fixative and wash twice with distilled water, add the newly prepared Bodipy493 / 503 staining solution to stain for 10 minutes and then remove the staining solution, wash 3 to 5 times with PBS, add an appropriate volume of Staining Solution, incubate at room temperature in the dark for 10 minutes, wash twice with PBS, and soak the stained cells in PBS and observe and photograph them under a fluorescence microscope.
[0051] Test results: Figure 5As shown, compared with the model group, both low and high doses of angelica lactone A could significantly improve lipid accumulation in L02 and HepG2 hepatocytes.
[0052] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. Use of angelica lactone A in the preparation of a drug for preventing and / or treating fatty hepatitis associated with metabolic dysfunction.
2. The use according to claim 1, characterized in that: The drug is a drug capable of improving weight gain or weight loss caused by metabolic dysfunction-related fatty hepatitis.
3. The use according to claim 1, characterized in that: The drug is a drug that can reduce the ALT level and / or AST level in serum.
4. The use according to claim 1, characterized in that: The drug is a drug that can reduce the TC content and / or TG content in serum.
5. The use according to claim 1, characterized in that: The drug is a drug capable of reducing the number of lipid droplet vacuoles and ballooning.
6. The use according to claim 1, characterized in that: The drug is a drug capable of improving liver fatty degeneration, lipid accumulation, inflammation in liver lobule or liver fibrosis.
7. The use according to claim 1, characterized in that: The drug is a drug capable of improving lipid deposition in normal human liver cells or lipid deposition in human liver cancer cells.
8. The use according to any one of claims 1 to 7, characterized in that: The dosage of angelica lactone A is 10 to 20 mg / kg.
9. The use according to any one of claims 1 to 7, characterized in that: The drug is in the form of tablets, capsules, granules, oral liquids, premixes, pills or sustained-release preparations for oral administration, or ointments or injections for non-oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents.
10. A drug for preventing and / or treating metabolic dysfunction-related fatty liver disease, characterized in that: It comprises angelica lactone A and one or more pharmaceutically acceptable carriers and / or excipients, or comprises angelica lactone A and other drugs for treating fatty liver disease associated with metabolic dysfunction.
Citation Information
Patent Citations
Pharmacological use of levistilide A
CN102772400A
Traditional Chinese medicine composition for treating non-alcoholic steatohepatitis as well as preparation method and application thereof
CN118021864A
